MyFinsight
Home
Blog
About
Contact
Download
Download image
Cash and cash
equivalents
$139,220,208
Marketable securities
$39,543,820
Prepaid research and
development
$1,001,993
Prepaid expenses and
other current assets
$343,374
Total current assets
$180,109,395
Prepaid research and
development, noncurrent
$1,000,000
Amount held as a
retainer
$95,121
Total assets
$181,204,516
Total liabilities and
stockholders' equity
$181,204,516
Total stockholders'
equity
$172,903,679
Total liabilities
$8,300,837
Accumulated deficit
-$142,679,800
Additional paid-in capital
$315,429,986
Total current
liabilities
$8,300,837
Common stock, 0.001 par
value 500,000,000 and...
$131,691
Accumulated other
comprehensive income (loss)
$21,802
Accrued expenses and
other current...
$4,081,282
Contingent consideration
liability
$3,061,501
Accounts payable
$1,158,054
Back
Back
Balance Sheet
source: myfinsight.com
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)